Ladenburg Thalmann Increases PT on Questor Pharmaceuticals to $49

Ladenburg Thalmann has increased its PT on Questor Pharmaceuticals

from $46 to $49 and has maintained its Buy rating on the company in a research report out today. In the report, Ladenburg Thalmann writes, "We believe QCOR is making substantial but justifiable investments not only to strengthen its commercial footprint in the most attractive areas in the near term (nephritic syndrome) but also for long term sustainability of the business. We welcome management's decision to strengthen internal compliance systems and to makeimportant R&D investments not only to document the potential future commercial expansion of Acthar but also to gain better understanding of the mechanism of action of Acthar (for the potential development of future therapeutics)." Shares of Questor Pharmaceuticals are currently trading at $37.31, up 7.40% from yesterday's close.